ViCentra Starts Commercial Production of Kaleido Consumables

Overview

• ViCentra began commercial-scale production of Kaleido infusion sets and insulin cartridges with Phillips Medisize on May 28, 2026, moving from product launch toward industrialized supply.
• The partnership more than triples ViCentra’s consumables capacity, with an initial scale the company says can support over 17,000 users.
• ViCentra says volume manufacturing at Phillips Medisize will lower per-unit costs and drive gross-margin expansion, a claim that depends on successful volume ramps and supply-chain execution.
• The increased supply is meant to let ViCentra add thousands of users in Germany, the Netherlands and France in the second half of 2026 while the company uses $98 million raised in its Series D to fund the push.
• Kaleido is sold in Europe as a smartphone-controlled hybrid closed-loop system that pairs two durable, rechargeable patch pumps and three-day infusion sets with Diabeloop’s DBLG2 algorithm and the Dexcom G7 CGM, and ViCentra faces established pump makers and new entrants as it prepares U.S. market entry and navigates reimbursement and regulatory hurdles.